このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Solasia Pharma K.K 将来の成長

Future 基準チェック /56

Solasia Pharma K.Kは、64.7%と36%でそれぞれ年率64.7%で利益と収益が成長すると予測される一方、EPSはgrowで66.4%年率。

主要情報

64.7%

収益成長率

66.4%

EPS成長率

Biotechs 収益成長	20.3%
収益成長率	36.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

TSE:4597 - アナリストの将来予測と過去の財務データ ( )JPY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2,829	96	142	203	1
12/31/2025	1,717	-926	-937	-753	1
12/31/2024	1,657	-538	-544	-501	1
3/31/2024	408	-1,181	-746	-746	N/A
12/31/2023	617	-1,112	-359	-359	N/A
9/30/2023	1,209	-1,267	-1,240	-1,240	N/A
6/30/2023	1,432	-1,738	-1,839	-1,441	N/A
3/31/2023	1,199	-2,174	-1,681	-1,282	N/A
12/31/2022	1,092	-2,548	-2,477	-2,074	N/A
9/30/2022	761	-2,416	-1,980	-1,520	N/A
6/30/2022	470	-2,331	-2,380	-2,214	N/A
3/31/2022	581	-2,437	-2,558	-2,392	N/A
12/31/2021	559	-2,478	-2,636	-2,473	N/A
9/30/2021	450	-4,301	-2,711	-2,595	N/A
6/30/2021	492	-4,249	-2,478	-2,360	N/A
3/31/2021	389	-4,252	-2,857	-2,688	N/A
12/31/2020	454	-4,127	-2,960	-2,789	N/A
9/30/2020	1,306	-2,132	-1,911	-1,699	N/A
6/30/2020	1,420	-2,046	-1,788	-1,676	N/A
3/31/2020	1,405	-1,838	-1,045	-980	N/A
12/31/2019	1,310	-1,867	-1,560	-828	N/A
9/30/2019	499	-2,561	-2,607	-1,846	N/A
6/30/2019	364	-2,599	-2,751	-1,969	N/A
3/31/2019	372	-2,662	-3,250	-2,381	N/A
12/31/2018	318	-2,422	-2,580	-2,323	N/A
9/30/2018	111	-2,129	-2,536	-2,238	N/A
6/30/2018	489	-1,378	-1,965	-1,440	N/A
3/31/2018	414	-1,086	-1,685	-1,169	N/A
12/31/2017	410	-1,007	N/A	-911	N/A
9/30/2017	709	-493	N/A	N/A	N/A
12/31/2016	501	-762	N/A	-464	N/A
12/31/2015	229	-917	N/A	N/A	N/A
12/31/2014	11	-677	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 4597は今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 0.2% ) よりも高い成長率であると考えられます。

収益対市場: 4597今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 4597今後 3 年以内に収益を上げることが予想されます。

収益対市場: 4597の収益 ( 36% ) JP市場 ( 4.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: 4597の収益 ( 36% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 4597の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Solasia Pharma K.K 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024

Consensus EPS estimates fall by 36%, revenue upgraded

Forecast breakeven date pushed back to 2026

Consensus revenue estimates fall by 66%

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Recent updates

First quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥1.44 loss in 1Q 2023)

Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Profitability

Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited

Consensus EPS estimates fall by 36%, revenue upgraded

Forecast breakeven date pushed back to 2026

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited

Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 66%

New major risk - Financial position

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Solasia Pharma K.K. to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: JP¥1.97 loss per share (vs JP¥4.95 loss in 3Q 2022)

Second quarter 2023 earnings released: JP¥1.17 loss per share (vs JP¥4.38 loss in 2Q 2022)

First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥4.61 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023

Solasia Pharma K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. (TSE:4597) from ITOCHU Corporation (TSE:8001).

Third quarter 2022 earnings released: JP¥4.95 loss per share (vs JP¥5.46 loss in 3Q 2021)

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Launch of Darvias in Japan

Second quarter 2022 earnings released: JP¥4.38 loss per share (vs JP¥5.67 loss in 2Q 2021)

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Solasia Pharma K.K. announced that it expects to receive ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. Announces an Organoarsenic Drug "Darvias® Injection 135Mg" (Sp-02, Hereinafter Darvias®) Has Been Approved for Relapsed or Refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare

First quarter 2022 earnings released: JP¥4.61 loss per share (vs JP¥5.22 loss in 1Q 2021)

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. to Report Q3, 2022 Results on Nov 11, 2022

Solasia Pharma K.K. announced that it expects to receive ¥3.44289 billion in funding from Macquarie Group Limited

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K., Annual General Meeting, Feb 24, 2022

Third quarter 2021 earnings released: JP¥5.46 loss per share (vs JP¥5.71 loss in 3Q 2020)

Second quarter 2021 earnings released: JP¥5.67 loss per share (vs JP¥6.36 loss in 2Q 2020)

Solasia Pharma K.K. Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan

First quarter 2021 earnings released: JP¥5.22 loss per share (vs JP¥4.54 loss in 1Q 2020)

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K. to Report Q1, 2021 Results on May 12, 2021

New 90-day high: JP¥158

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K., Annual General Meeting, Mar 29, 2021

Solasia Pharma K.K. to Report Fiscal Year 2020 Results on Feb 16, 2021

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Year Ending December 31, 2020

New 90-day low: JP¥123

Solasia Pharma K.K. announced that it expects to receive ¥13.44 million in funding from Macquarie Group Limited

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘